Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline

Recommendations:

BRCA1/2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and select patients >65 years based on personal history, family history, ancestry, or eligibility for poly(ADP-ribose) polymerase (PARP) inhibitor therapy.

Source: https://ascopubs.org/doi/full/10.1200/JCO.23.02225